Bolt Biotherapeutics, Inc.
BOLT
$0.37
$0.0154.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -10.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -10.51% | |||
| Cost of Revenue | -14.97% | -10.68% | |||
| Gross Profit | 7.29% | 10.69% | |||
| SG&A Expenses | 3.90% | -22.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.89% | -13.41% | |||
| Operating Income | 4.71% | 13.60% | |||
| Income Before Tax | -5.01% | 28.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.01% | 28.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.01% | 28.40% | |||
| EBIT | 4.71% | 13.60% | |||
| EBITDA | 4.75% | 13.85% | |||
| EPS Basic | -109.86% | 28.64% | |||
| Normalized Basic EPS | -93.39% | 14.19% | |||
| EPS Diluted | -109.86% | 28.64% | |||
| Normalized Diluted EPS | -93.39% | 14.19% | |||
| Average Basic Shares Outstanding | 0.09% | 0.32% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||